ICCC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ImmuCell Corp (ICCC) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is showing weak financial performance, no significant positive trading trends, and a high probability of price decline in the short to medium term. Additionally, there are no positive catalysts or signals from Intellectia Proprietary Trading Signals to support a buy decision.
The MACD is slightly positive and expanding, indicating mild bullish momentum, but the RSI is neutral at 64.421, and moving averages are converging, showing no strong trend. Support and resistance levels suggest limited upside potential with a pivot at 6.328 and resistance at 6.595. Stock trend analysis predicts a high probability of price decline (-6.94% in the next week and -19.94% in the next month).
Gross margin increased by 4.46% YoY, which is a minor positive factor.
Revenue dropped by -1.61% YoY, net income plummeted by -653.68% YoY, and EPS declined by -616.67% YoY. No recent news or significant trading trends from hedge funds or insiders. Stock trend analysis predicts a high probability of price decline in the short to medium term.
In Q4 2025, the company's revenue dropped to $7,626,000 (-1.61% YoY), net income fell to -$2,849,000 (-653.68% YoY), and EPS dropped to -0.31 (-616.67% YoY). Gross margin increased to 38.16% (+4.46% YoY), but overall financial performance is weak.
No analyst ratings or price target changes available.
